Full-Time

Director – Global Patient Safety Science

Posted on 12/13/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$204k - $255kAnnually

+ Competitive Cash Compensation + Equity Awards + Benefits + Learning and Development Opportunities

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Risk Management
Google Cloud Platform

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 5 or more years of drug development experience in the pharmaceutical or related industry, of which at least 2 years include prior Safety Science experience, which includes performance of medical review, safety surveillance/signal detection, and other related risk management activities.
  • The ability to demonstrate a broad understanding of safety risk management (e.g., via demonstrable knowledge of the application of GVP, GCP, and CTR requirements)
  • A relevant postgraduate qualification (e.g., MD, PharmD, PhD/MSc in a Life sciences discipline, or other post-graduate health professional qualifications).
  • Proven success in creating and sustaining strong relationships with internal and external business partners across an organization to create positive partnerships.
Responsibilities
  • Responsible for safety surveillance and risk management activities including, but not limited to medical review of ICSRs, routine review of safety data, and pertinent scientific literature articles. Contribute to the review of assessments for safety signals or in response to Regulatory Authority requests.
  • Acquire and contribute knowledge of relevant drug class and/or competitor safety issues. Lead the development of safety surveillance strategy, identify potential clinical safety issues, and recommend appropriate risk mitigation measures.
  • Establish and maintain collaborative working relationships with all key stakeholders (e.g., clinical study teams, safety CROs, business partners) which require expert contribution to the development of the product safety strategy.
  • Conduct risk management activities including preparation and maintenance of relevant sections of clinical trial protocols, IBs (including the reference safety information section), ICFs, DSURs, RMPs, CCDS, and labelling, as required.
  • Contribute to regulatory authority submissions (Investigational New Drug applications, New Drug Applications, Marketing Authorization Applications, etc.).
  • Accountable for the safety components of study reports (i.e., CSRs), aggregate reports, and other regulatory documents.
  • Consistently comply with all governing laws, regulations, RevMed standard operating procedures (SOPs) and other guidelines.
Desired Qualifications
  • Demonstrated ability to lead and influence, with and without authority, in a global matrix environment.
  • Evidence of proactive, structured thinking with the ability to rapidly respond to an evolving and complex environment.
  • Apply complex data analysis / statistical methods to evaluate, interpret and present scientific data with clarity.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

INACTIVE